CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer
Washington University School of Medicine
Washington University School of Medicine
Seagen Inc.
Tizona Therapeutics, Inc
Genentech, Inc.
Amgen
Rondo Therapeutics
Incyte Corporation
Toray Industries, Inc
Sotio Biotech Inc.
Carisma Therapeutics Inc
Inhibrx Biosciences, Inc
NGM Biopharmaceuticals, Inc
ADC Therapeutics S.A.
NGM Biopharmaceuticals, Inc
Celldex Therapeutics
University of Florida
Fate Therapeutics
Xencor, Inc.
M.D. Anderson Cancer Center
Halozyme Therapeutics